Connor, Clark & Lunn Investment Management (CC&L)’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-153,058
| Closed | -$1.47M | – | 1652 |
|
|
2024
Q4 | $1.47M | Sell |
153,058
-206,139
| -57% | -$1.98M | 0.01% | 817 |
|
|
2024
Q3 | $1.03M | Buy |
359,197
+138,510
| +63% | +$396K | 0.01% | 879 |
|
|
2024
Q2 | $644K | Sell |
220,687
-283,073
| -56% | -$827K | ﹤0.01% | 977 |
|
|
2024
Q1 | $1.61M | Buy |
503,760
+129,238
| +35% | +$412K | 0.01% | 733 |
|
|
2023
Q4 | $1.26M | Buy |
374,522
+31,665
| +9% | +$106K | 0.01% | 793 |
|
|
2023
Q3 | $816K | Buy |
342,857
+223,280
| +187% | +$531K | ﹤0.01% | 884 |
|
|
2023
Q2 | $210K | Buy |
+119,577
| New | +$210K | ﹤0.01% | 1182 |
|